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Background
Polyarteritis nodosa (PAN) is a necrotizing vasculitis sel-
dom reported on childhood, with a severe prognosis.
Patients
We report two sisters (16 and 8 years old) with PAN refrac-
tory to different drugs who had a persistent improvement
over 5-years of thalidomide.
In the older, the presenting symptoms were fever and
migrant arthralgias. At onset, she was 6 year old. Labora-
tory work-up showed increased ESR, CRP, PTL count, and
anaemia. Over time she developed ischemic colitis and a
transient cerebral ischemic attack. Cerebral Angio MRI
revealed multiple periventricular hyperintensities
prompting the diagnosis of PAN. Steroids, cyclophospha-
mide, methotrexate, and azathioprine were unsuccessful,
and the disease was complicated by neuropathy and
ischemic lesions of several digits. Thalidomide was started
in December 2003; since then, the disease is stable and
laboratory work up normal. First clinical features of the
younger sister occurred at three years of age. She had an
acute stroke. Following hypertension, renal disease and
neuropathy, PAN was diagnosed. Steroids, azathioprine
and cyclophosphamide were given with scarce benefit.
After another ischemic cerebrovascular event, thalido-
mide was effective in controlling the disease activity.
No side effects have been observed.
Conclusion
Both our patients refractory to steroids and immunosup-
pressants had a significant improvement when thalido-
mide was introduced. No flares have been observed
during a 5-year follow-up. Although the exact mechanism
of action is not fully understood, thalidomide mainly pre-
scribed in connective diseases, could be considered an
alternative therapy in severe PAN.
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